NCT04578444: An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Solid Tumors

NCT04578444
Breast Cancer Type: HER2+
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Available

Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active untreated brain metastasis requiring local therapy – see trial for details; Patients with symptomatic leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04578444

Comments are closed.

Up ↑